Literature DB >> 27740898

Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background.

Norihide Yoneda1, Osamu Matsui1, Azusa Kitao1, Kazuto Kozaka1, Satoshi Kobayashi1, Motoko Sasaki1, Kotaro Yoshida1, Dai Inoue1, Tetsuya Minami1, Toshifumi Gabata1.   

Abstract

Gadoxetic acid is a contrast agent for magnetic resonance (MR) imaging with hepatocyte-specific properties and is becoming increasingly important in detection and characterization of hepatocellular carcinoma and benign hepatocellular nodules, including focal nodular hyperplasia (FNH), nodular regenerative hyperplasia (NRH), hepatocellular adenoma (HCA), and dysplastic nodule. In these hepatocellular nodules, a positive correlation between the grade of membranous uptake transporter organic anion-transporting polypeptide (OATP) 1B3 expression and signal intensity in the hepatobiliary (HB) phase has been verified. In addition, it has been clarified that OATP1B3 expression is regulated by activation of β-catenin and/or hepatocyte nuclear factor 4α. On the other hand, recent studies have also revealed some of the background molecular mechanisms of benign hepatocellular nodules. FNH commonly shows iso- or hyperintensity in the HB phase with equal or stronger OATP1B3 expression, with map-like distribution of glutamine synthetase (a target of Wnt/β-catenin signaling) and OATP1B3 expression. NRH shows doughnut-like enhancement with hypointensity in the central portion in the HB phase with OATP1B3 expression. The majority of HCAs show hypointensity in the HB phase, but β-catenin-activated HCA exclusively demonstrates iso- or hyperintensity with increased expression of nuclear β-catenin, glutamine synthetase, and OATP1B3. Dysplastic nodule commonly shows iso- or hyperintensity in the HB phase with similar to increased OATP1B3 expression, but one-third of high-grade dysplastic nodules can be demonstrated as a hypointense nodule with decreased OATP1B3 expression. Knowledge of these background molecular mechanisms of gadoxetic acid-enhanced MR imaging is important not only for precise imaging diagnosis but also understanding of the pathogenesis of benign hepatocellular nodules. ©RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27740898     DOI: 10.1148/rg.2016160037

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  21 in total

1.  Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.

Authors:  Edouard Reizine; Maxime Ronot; Frederic Pigneur; Yvonne Purcell; Sebastien Mulé; Marco Dioguardi Burgio; Julien Calderaro; Giuliana Amaddeo; Alexis Laurent; Valérie Vilgrain; Alain Luciani
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

2.  Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: imaging and clinicopathological features.

Authors:  Kazuto Kozaka; Satoshi Kobayashi; Norihide Yoneda; Azusa Kitao; Kotaro Yoshida; Dai Inoue; Takahiro Ogi; Wataru Koda; Yasunori Sato; Toshifumi Gabata; Osamu Matsui
Journal:  Eur Radiol       Date:  2019-07-05       Impact factor: 5.315

Review 3.  Magnetic Resonance Imaging of Hepatic Adenoma Subtypes.

Authors:  Vincenzo K Wong; Alice W Fung; Khaled M Elsayes
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 4.  [CT and MRI of the liver: when, what, why?]

Authors:  J Budjan; S O Schoenberg; U I Attenberger
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

Review 5.  Hepatocyte-specific contrast media: not so simple.

Authors:  Andrew T Trout; Alexander J Towbin; Ethan A Smith; Anita Gupta; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2018-08-04

Review 6.  Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI.

Authors:  Cathryn L Hui; Marcela Mautone
Journal:  Br J Radiol       Date:  2020-06-01       Impact factor: 3.039

Review 7.  Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.

Authors:  Rama S Ayyala; Sudha A Anupindi; Michael S Gee; Andrew T Trout; Michael J Callahan
Journal:  Pediatr Radiol       Date:  2019-07-26

8.  Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.

Authors:  Edouard Reizine; Giuliana Amaddeo; Frederic Pigneur; Laurence Baranes; François Legou; Sebastien Mulé; Benhalima Zegai; Vincent Roche; Alexis Laurent; Alain Rahmouni; Julien Calderaro; Alain Luciani
Journal:  Eur Radiol       Date:  2018-05-02       Impact factor: 5.315

9.  cDNA Microarray Analysis and Influx Transporter OATP1B1 in Liver Cells After Exposure to Gadoxetate Disodium, a Gadolinium-based Contrast Agent in MRI Liver Imaging.

Authors:  Chi-Cheng Lu; Wen-Kang Chen; Jo-Hua Chiang; Yuh-Feng Tsai; Yu-Ning Juan; Ping-Chin Lin; Yeu-Sheng Tyan; Jai-Sing Yang
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

10.  OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI.

Authors:  Xiaojiao Zhou; Liling Long; Zhiqing Mo; Yajuan Li
Journal:  Cancer Manag Res       Date:  2021-02-09       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.